Swedish Orphan Biovitrum has agreed to an additional Kineret® drug campaign with Amgen
Stockholm, Sweden - March 12, 2009 - Swedish Orphan Biovitrum (STO: BVT) todayannounced an agreement with Amgen to run an additional Kineret(®) bulk drugcampaign. In addition, Swedish Orphan Biovitrum will pay to buy-out previouslyagreed future sales milestones for Kineret® and Kepivance®.Under the agreement Amgen will run an additional Kineret(®) campaign at itsBoulder facility in Colorado, as well as manufacture drug product at itsfacility in Puerto Rico. The objective of this additional campaign is to meet anexpected increased market demand of Kineret(®) until Swedish Orphan